Max S. Topp, MD, discusses the safety profile of glofitamab in combination with R-CHOP in patients with diffuse large B-cell lymphoma.
Max S. Topp, MD
Advertisement
Articles by Max S. Topp, MD
Max S. Topp, MD, discusses the efficacy of the combination of glofitamab plus R-CHOP from a phase 1 trial done in previously untreated patients with diffuse large B-cell lymphoma.
Advertisement
Latest Updated Articles
Dr. Max Topp on the TOWER study and Blinatumomab in ALLPublished: July 28th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5